Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.70 |
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725211 | 1.00 | GLP1R (0.70) | GLP1RNOD1 | |
| SCHEMBL23106986 | 0.98 | GLP1R (0.68) | GLP1RNOD1 | |
| SCHEMBL26076118 | 0.94 | GLP1R (0.77) | GLP1RNOD1 | |
| SCHEMBL15276351 | 0.93 | NOD1 (0.71) | GLP1RNOD1 | |
| SCHEMBL19034936 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034927 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034808 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034989 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL19034933 | 0.92 | GLP1R (0.61) | GLP1RNOD1 | |
| SCHEMBL18117511 | 0.92 | GLP1R (0.61) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215587-A1 | TREATMENT OF MYASTHENIA GRAVIS WITH ZILUCOPLAN | UCB Biopharma SRL (BE) | 2023-11-09 | — | — | WO | disclosed |
| US-11723949-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723949-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11707503-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707503-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3685847-B1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220211799-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220160820-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220133841-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | RA PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-11123399-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200038477-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190307835-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10435438-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10328115-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190119328-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10208089-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180193408-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180021402-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-01-25 | — | — | US | disclosed |
| WO-2017105939-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707503-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885 |
| US-20180021402-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885 |
| US-20220160820-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C5, C1QBP, C9 | GLP1R 3466/4885NOD1 1255/4885 |
| US-11123399-B2 | Modulators of complement activity | C1QBP, C5, C3AR1 | GLP1R 1243/4885NOD1 1668/4885 |
| US-20220211799-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | C5, C9, C1QBP | GLP1R 571/4885NOD1 2400/4885 |
| US-20190119328-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | GLP1R 3416/4885NOD1 1423/4885 |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | GLP1R 3416/4885NOD1 1423/4885 |
| US-20190307835-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885 |
| US-10328115-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885 |
| US-11723949-B2 | Modulators of complement activity | C1QBP, C5, C3AR1 | GLP1R 1243/4885NOD1 1668/4885 |
| US-20200038477-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C1QBP, C5, C3AR1 | GLP1R 1243/4885NOD1 1668/4885 |
| US-10435438-B2 | Modulation of complement activity | C5, C3AR1, CFH | GLP1R 3416/4885NOD1 1423/4885 |
| US-20220133841-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | ACHE, C5, BCHE | GLP1R 2348/4885NOD1 3583/4885 |
| US-10208089-B2 | Modulation of complement activity | C5, C3AR1, CFH | GLP1R 3416/4885NOD1 1423/4885 |
| US-20180193408-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.